|
|
|
| Comparetive study on the efficacy of ethinylestradiol cyproterone tablets and metformin for treating patients with polycystic ovary syndrome |
| Qingdao Jiaozhou Central Hospital, Jiaozhou, Shandong Province, 266300 |
|
|
|
|
Abstract To explore the effect of metformin for treating patients with polycystic ovary syndrome (PCOS), and to study its influence on the sex hormones levels, pregnancy rate and pregnancy complications of the patients. Methods: A randomized controlled trial was used in this study. From July 2021 to January 2023, 210 patients with PCOS were selected and were divided into control group (102 patients treated with ethinylestradiol cyproterone tablets) and observation group (108 patients treated with metformin) according to random number method. The values of the general condition indexes, such as body weight, body mass index (BMI) and waist-to-hip ratio (WHR), the levels of glucose metabolism indexes, such as fasting plasma glucose (FPG), fasting insulin (FINS) and homeostasis model assessment of insulin resistance (HOMA-IR), the levels of lipid metabolism indexes, such as total cholesterol (TC), apolipoprotein A (apoA), high density lipoprotein (HDL-C) and low density lipoprotein (LDL-C), and the levels of sex hormone indexes, such as luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone (T) and estradiol (E2) of the patients before and after treatment were compared between the two groups. The pregnancy rate and the complications situation of the patients during pregnancy were followed up for 9 months after treatment continually. Results: After treatment, the values of body weight, BMI and WHR of the patients in the two groups had decreased significantly, and which (63.0±8.7 kg, 26.1±2.9 kg/m2 and 0.73±0.15) of the patients in the observation group were significantly lower than those (66.4±9.7 kg, 27.6±3.5 kg/m2 and 0.82±0.19) of the patients in the control group. The levels of FPG (4.01±0.96 mmol/L), FINS (18.69±2.94 mU/L) and the HOMA-IR value (3.30±0.88) of the patients in the observation group were significantly lower than those (4.96±1.10 mmol/L, 22.37±3.82 mU/L and 4.93±1.10) of the patients in the control group. The levels of TC, HDL-C and LDL-C of the patients in the two groups had decreased significantly, and which of the patients in the observation group were significantly lower than those of the patients in the control group. The apoA level of the patients in the two groups had increased significantly, and which of the patients in the observation group was significantly higher than that of the patients in the control group. The levels of LH, T and E2 of the patients in the two groups had decreased significantly and the FSH level of the patients in the two groups had increased significantly, and the changes of which of the patients in the observation group were significantly greater than those of the patients in the control group (all P<0.05). Conclusion: Metformin for treating the patients with PCOS has better efficacy, which is conducive to improving the metabolism ability of the blood glucose and lipid, improving the endocrine function and to correcting the metabolic disorders of the patients, thus having a positive effect on improving the pregnancy rate and lowering the risk of the complications of the patients during pregnancy.
|
|
|
|
|
|
|
|
|
